18F-FLT PET/CT 在肺癌根治性放疗后复发诊断中较 18F-FDG PET/CT 增益
18F-FLT PET/CT 特异性更高(HDV 96% vs 71%,P=0.0039;患者层面 90% vs 55%,P=0.0020),但敏感性更低;在 18F-FDG PET/CT 阳性或不确定时加做 18F-FLT PET/CT 可提高诊断价值,cRT 后获益最大。
要点
- 18F-FLT PET/CT 特异性高于 18F-FDG PET/CT,cRT 后差异大于 SBRT 后。
- 18F-FLT PET/CT 敏感性低于 18F-FDG PET/CT,患者层面差异有统计学意义。
- FDG 阳性或不确定时加做 FLT 可提高诊断价值,双阳性时恶性概率升至 100%。
核心结论
- 在疑似肺癌根治性放疗后复发的患者中,18F-FLT PET/CT 可为 18F-FDG PET/CT 增加诊断价值,cRT 后诊断影响最大。
- 建议在既往照射体积内 18F-FDG PET/CT 结果不确定或阳性、且难以获得组织学确认时加做 18F-FLT PET/CT。
研究设计与样本
- 在高剂量区内和患者层面分别分析敏感性与特异性,并评估边缘差异和观察者间一致性。
主要发现
- 特异性:18F-FLT PET/CT 高于 18F-FDG PET/CT(HDV 96% [95%CI 87-100] vs 71% [95%CI 57-83],P=0.0039;患者层面 90% [95%CI 73-98] vs 55% [95%CI 36-74],P=0.0020)。
- 敏感性:18F-FLT PET/CT 低于 18F-FDG PET/CT(HDV 69% [95%CI 41-89] vs 94% [95%CI 70-100],P=0.1250;患者层面 70% [95%CI 51-84] vs 94% [95%CI 80-99],P=0.0078)。
- 18F-FLT PET/CT 与 18F-FDG PET/CT 的特异性差异在 cRT 后高于 SBRT 后。
- 在 18F-FDG PET/CT 阳性或不确定时加做 18F-FLT PET/CT,较单用 18F-FDG PET/CT 提高诊断价值。
- 在 cRT 高剂量区,恶性概率从单用 18F-FDG PET/CT 的 67% 升至两种示踪剂均阳性时的 100%。
关键数值与推荐
- 特异性比较:HDV 96% vs 71%(P=0.0039),患者层面 90% vs 55%(P=0.0020),均为 18F-FLT PET/CT vs 18F-FDG PET/CT。
- 敏感性比较:HDV 69% vs 94%(P=0.1250),患者层面 70% vs 94%(P=0.0078),均为 18F-FLT PET/CT vs 18F-FDG PET/CT。
- cRT 高剂量区恶性概率:单用 18F-FDG PET/CT 为 67%,两种示踪剂均阳性时为 100%。
临床怎么用
- 对根治性放疗后疑似复发、尤其 cRT 后且组织学确认困难者,可在 18F-FDG PET/CT 阳性或不确定时加做 18F-FLT PET/CT 以提高特异性。
- 判读时需注意 18F-FLT PET/CT 敏感性较低,阴性结果不能单独排除复发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diagnosing relapse after radiotherapy for lung cancer is challenging. The specificity of both CT and 18F-FDG PET/CT is low because of radiation-induced changes. 3'-deoxy-3'-18F-fluorothymidine (18F-FLT) PET has previously demonstrated higher specificity for malignancy than 18F-FDG PET. We investigated the value of 18F-FLT PET/CT for diagnosing relapse in irradiated lung cancer. Methods: Patients suspected of relapse of lung cancer after definitive radiotherapy (conventional fractionated radiotherapy [cRT] or stereotactic body radiotherapy [SBRT]) were included. Sensitivity and specificity were analyzed both within the irradiated high-dose volume (HDV) and on a patient basis. Marginal differences and interobserver agreement were assessed. Results: Sixty-three patients who had received radiotherapy in 70 HDVs (34 cRT; 36 SBRT) were included. The specificity of 18F-FLT PET/CT was higher than that of 18F-FDG PET/CT (HDV, 96% [95% CI, 87-100] vs. 71% [95% CI, 57-83] [P = 0.0039]; patient-based, 90% [95% CI, 73-98] vs. 55% [95% CI, 36-74] [P = 0.0020]). The difference in specificity between 18F-FLT PET/CT and 18F-FDG PET/CT was higher after cRT than after SBRT. The sensitivity of 18F-FLT PET/CT was lower than that of 18F-FDG PET/CT (HDV, 69% [95% CI, 41-89] vs. 94% [95% CI, 70-100] [P = 0.1250]; patient-based, 70% [95% CI, 51-84] vs. 94% [95% CI, 80-99] [P = 0.0078]). Adding 18F-FLT PET/CT when 18F-FDG PET/CT was positive or inconclusive improved the diagnostic value compared with 18F-FDG PET/CT alone. In cRT HDVs, the probability of malignancy increased from 67% for 18F-FDG PET/CT alone to 100% when both tracers were positive. Conclusion:18F-FLT PET/CT adds diagnostic value to 18F-FDG PET/CT in patients with suspected relapse. The diagnostic impact of 18F-FLT PET/CT was highest after cRT. We suggest adding 18F-FLT PET/CT when 18F-FDG PET/CT is inconclusive or positive within the previously irradiated volume to improve diagnostic value in patients for whom histologic confirmation is not easily obtained.
引用
- Christensen TN, Langer SW, Persson G, et al. 18F-FLT PET/CT Adds Value to 18F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. J Nucl Med. 2020. PMID: 33037090. doi:10.2967/jnumed.120.247742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。